Searched for
TIRZEPATIDE
Losing weight fast on GLP-1 drugs? Your hair could be the next thing to goDermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen efflu...02 Aug, 2026, 12.46 PM IST- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...27 Jul, 2026, 06.44 AM IST
- Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug adsNovo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers...24 Jul, 2026, 06.58 PM IST
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...23 Jul, 2026, 10.24 PM IST
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...22 Jul, 2026, 03.00 PM IST
- Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...09 Jul, 2026, 12.43 AM IST
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...09 Jun, 2026, 05.30 AM IST
- Rs 70,00,000 worth fake Mounjaro injections seized in Gurgaon; Police expose illegal weight-loss drug racket in NCRGurgaon Drug Racket: Authorities in Gurgaon have busted a major illegal pharmaceutical racket involving spurious Mounjaro KwikPen (tirzepat...20 Apr, 2026, 02.01 PM IST
- Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market shareNovo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...09 Mar, 2026, 12.27 AM IST
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...24 Feb, 2026, 01.51 AM IST
- Cipla launches drug for obesity, diabetesCipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...10 Dec, 2025, 07.34 PM IST
- Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow TuckerEli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...19 Nov, 2025, 07.05 PM IST
- Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...23 Oct, 2025, 08.32 PM IST
- Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors saySemaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective ...02 Oct, 2025, 03.15 PM IST
- ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears riseTirzepatide and semaglutide dominate India's anti-obesity drug market, holding a 75% share. While seen as vital tools by doctors, experts c...16 Jul, 2025, 12.20 AM IST
- Waiting for a wonder drug? The weight just got longerEli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the dru...04 Jul, 2024, 05.30 AM IST
- Eli Lilly's new diabetes drug could boost the stock, says SVB SecuritiesSVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...23 May, 2022, 09.32 PM IST
Load More
